Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells
- 20 August 2004
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 321 (2), 403-412
- https://doi.org/10.1016/j.bbrc.2004.06.160
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Site-Specific Mutagenesis of Mistletoe Lectin: The Role of RIP Activity in ApoptosisBiochemical and Biophysical Research Communications, 1999
- Characterization of recombinant and plant‐derived mistletoe lectin and their B‐chainsEuropean Journal of Biochemistry, 1999
- Cloning of the mistletoe lectin gene and characterization of the recombinant A‐chainEuropean Journal of Biochemistry, 1999
- Lectin‐induced increase in clonogenic growth of haematopoietic progenitor cellsEuropean Journal of Haematology, 1998
- Expression of N-Acetyl Galactosaminylated and Sialylated Glycans by Metastases Arising from Primary Breast CancerInvasion and Metastasis, 1998
- Mistletoe Lectin I-Induced Effects on Human Cytotoxic Lymphocytes. I. Synergism with Il-2 in the Induction of Enhanced Lak CytotoxicityImmunopharmacology and Immunotoxicology, 1998
- Comparison of ribosome-inactivating proteins in the induction of apoptosisToxicology Letters, 1997
- Mistletoe treatment for cancer review of controlled trials in humansPhytomedicine, 1994
- The site of action of the A‐chain of mistletoe lectin I on eukaryotic ribosomes The RNA N‐glycosidase activity of the proteinFEBS Letters, 1988
- Immunomodulatory Effects of Iscador: A Viscum album PreparationOncology, 1986